GlassScriptPhysician profile
Claire T Ronkartz
NPI 1447677711
$1,735.50
in general payments reported to CMS, 2019-2025
29 companies · $537 in 2025
The $537 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $512 · 2020: $139 · 2022: $124 · 2023: $223 · 2024: $200 · 2025: $537.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $960.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $960.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $291.55 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $263.27 | 2024-2025 | |
| Organogenesis INC. | $176.40 | 2022-2023 | Puraply |
| Novo Nordisk INC | $109.41 | 2019-2024 | Ozempic, Rybelsus |
| Lilly USA, LLC | $94.90 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Merck Sharp & Dohme LLC | $88.87 | 2019-2025 | Capvaxive, Gardasil 9 |
| Bioventus LLC | $82.33 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $66.96 | 2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.82 | 2019-2024 | Jardiance |
| Exact Sciences Corporation | $50.18 | 2023-2025 | Cologuard Collection Kit |
| Allergan, INC. | $44.91 | 2019 | |
| Amgen INC. | $39.14 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $36.66 | 2019-2020 | |
| Ardelyx, INC. | $32.32 | 2024 | Ibsrela |
| Currax Pharmaceuticals LLC | $32.10 | 2020-2025 | Contrave |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $31.54 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.53 | 2020-2025 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $26.77 | 2019 | |
| Janssen Pharmaceuticals, INC | $26.53 | 2019-2020 | |
| Boston Scientific Corporation | $25.60 | 2025 | Watchman Flx |
| Ironshore Pharmaceuticals INC. | $24.21 | 2019 | |
| Nevro Corp. | $16.97 | 2019 | |
| Solventum Corporation | $16.86 | 2025 | Activ.A.C. |
| Adlon Therapeutics L.P. | $16.00 | 2019 | |
| Corvista Health, INC. | $13.55 | 2025 | Corvista System |
| Amarin Pharma, INC. | $12.83 | 2019 | |
| Shire North American Group INC | $12.07 | 2019 | |
| Pfizer INC. | $11.23 | 2019 | |
| Novartis Pharmaceuticals Corporation | $10.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Claire Ronkartz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.